Key facts
- This page summarizes Atlas Venture Fund X, L.P.'s Form 3 filing for Homology Medicines, Inc. (QTTB).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2024, 17:16.
Atlas Venture Fund X, L.P. - 25 Mar 2024 Form 3 Insider Report for Homology Medicines, Inc. (QTTB)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- QTTB
- Reported as of
- 25 Mar 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 Mar 2024, 17:16:23 UTC
- Prior SEC filing
- 13 Mar 2024
- Next SEC filing
- 09 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- Atlas Venture Fund X, L.P., By: Atlas Venture Associates X, L.P., its general partner, by Atlas Venture Associates X, LLC, its general partner, By: /s/ Ommer Chohan, Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Atlas Venture Fund X, L.P. filed Form 3 for Homology Medicines, Inc. (QTTB) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 13 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QTTB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 864,261
- Date
- 25 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
QTTB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 503,296
- Date
- 25 Mar 2024
- Ownership
- By Atlas Venture Opportunity Fund I, L.P.
- Footnotes
- F2
QTTB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 724,549
- Date
- 25 Mar 2024
- Ownership
- By Atlas Venture Opportunity Fund II, L.P.
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
Footnote F2
Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
Footnote F3
The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.